We’re proud to announce the successful closing of a funding round, with strategic participation from Wa’ed Ventures (by Aramco), Plug and Play Tech Center, and KAUST Innovation. These new investors join our existing backers, including Techstars and Lamarka, to further accelerate our mission.

This investment fuels the growth of TFscan, the world’s first regulatory-compliant, AI-powered Software as a Medical Device (SaMD) for diabetic foot screening. Recently approved by the Saudi Food and Drug Authority (SFDA), TFscan uses thermal imaging and advanced AI algorithms to detect early signs of diabetic foot ulcers (DFUs), enabling timely intervention and significantly reducing the risk of limb amputation.

“This funding validates both our vision and our team’s ability to execute,” said Dr. Mashari Alwashmi, CEO of Amplifai Health. “We’re thrilled to welcome new strategic partners who share our passion for transforming preventative care with AI.”

With the support of our investors and growing global recognition, Amplifai Health is well-positioned to scale impact, expand into new markets, and continue developing technologies that save limbs, and lives.